- Jazz Pharmaceuticals (NASDAQ:JAZZ +3.5%) and its recent acquisition Gentium launch Defitelio (defibrotide) in Germany and Austria.
- The rollout will continue in 27 additional European countries in 2014 and 2015.
- Defitelio is the first licensed product for severe hepatic veno-occlusive disease in patients over one month of age undergoing haematopoietic stem cell transplantation therapy.
- The European Commission approved the product in October.
- Consensus Q1 and Q2 estimates are earnings of $1.91 on revenues of $259M and $1.97 on revenues of $276.3M, respectively.
- Consensus estimates for 2014 and 2015 are earnings of $8.21 on revenues of $1.14B and $10.16 on revenues of $1.36B, respectively.
- 574 mutual funds have positions, up from 448 a year earlier.